- BEXSERO is a vaccine to help prevent invasive disease caused by Neisseria meningitidis serogroup B.
- BEXSERO is a vaccine to help prevent invasive disease caused by Neisseria meningitidis serogroup B.
- BEXSERO is a vaccine to help prevent invasive disease caused by Neisseria meningitidis serogroup B.
- BEXSERO is approved for vaccination of individuals from 2 months of age and older.3
- Do not have BEXSERO if you are allergic (hypersensitive) to the active substances or any of the other ingredients in BEXSERO.
- Please note that BEXSERO can only protect from meningococcal disease caused by Neisseria meningitidis group B.
- BEXSERO is not expected to provide protection against all circulating meningococcal group B types.
- There is an increased risk of fever in infants that receive BEXSERO. Paracetamol reduces the incidence and severity of fever and is recommended with every dose of BEXSERO in children under 2 years.3,6
- The safety and efficacy of BEXSERO in adults above 50 years of age have not been established.3
- Do not have BEXSERO if you are allergic (hypersensitive) to the active substances or any of the other ingredients in BEXSERO.
- Please note that BEXSERO can only protect from meningococcal disease caused by Neisseria meningitidis group B.
- BEXSERO is not expected to provide protection against all circulating meningococcal group B types.
- There is an increased risk of fever in infants that receive BEXSERO. Paracetamol reduces the incidence and severity of fever and is recommended with every dose of BEXSERO in children under 2 years.3,6
- The safety and efficacy of BEXSERO in adults above 50 years of age have not been established.3
Important safety information
- Do not have BEXSERO if you are allergic (hypersensitive) to the active substances or any of the other ingredients in BEXSERO.
- Please note that BEXSERO can only protect from meningococcal disease caused by Neisseria meningitidis group B.
- BEXSERO is not expected to provide protection against all circulating meningococcal group B types.
- There is an increased risk of fever in infants that receive BEXSERO. Paracetamol reduces the incidence and severity of fever and is recommended with every dose of BEXSERO in children under 2 years.3,6
- The safety and efficacy of BEXSERO in adults above 50 years of age have not been established.3
References
- Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397–403
- World Health Organization. Meningococcal meningitis. 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/meningitis. Accessed May 2024
- GlaxoSmithKline NZ, BEXSERO Data Sheet 2023. Available at: https://medsafe.govt.nz/profs/Datasheet/b/bexseroinj.pdf. Accessed: May 2024
- The Institute of Environmental Science and Research. Invasive Meningococcal Disease Report. Jan-Dec 2023. Available at: https://www.esr.cri.nz/digital-library/meningococcal-disease-report-jan-dec-2023/. Accessed May 2024
- New Zealand Pharmaceutical Schedule. 2024. Available at: https://schedule.pharmac.govt.nz/2024/03/01/Schedule.pdf. Accessed: May 2024
- Immunisation Advisory Centre (IMAC). Bexsero: A vaccine to protect against Meningococcal group B disease Fact Sheet. Available at: https://assets-global.website-files.com/637315ab5c5af16c7e809c42/646eb2afbdc7bb7502d6ff00_NonprogrammeVaccineBexseroImac20210701%20V07.pdf. Accessed: May 2024
- Ministry of Health website. Meningococcal disease (including meningitis). Summary tab. Available at: https://www.health.govt.nz/your-health/conditions-and-treatments/diseasesand-illnesses/meningococcal-disease-including-meningitis. Accessed May 2024
- Rosenstein NE, et al. Meningococcal disease. N Engl J Med 2001; 344(18):1378-88.
- Vetter V, Baxter R, Denizer G, et al. Routinely vaccinating adolescents against meningococcus: targeting transmission and disease. Expert Rev Vaccines. 15;5:641-658. doi:10.1586/14760584.2016.1130628
- Mayo Clinic. Symptoms and causes: meningitis. Available at: https://www.mayoclinic.org/diseases-conditions/meningitis/symptoms-causes/syc-20350508. Accessed: May 2024
- Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adol Health. 2010;46:S9-S15. doi:10.1016/j.jadohealth.2009.11.220
- Ministry of Health. Meningococcal Disease - Don’t Wait, Take Action. Available at: https://healthed.govt.nz/products/meningococcal-disease-dont-wait-take-action. Accessed: May 2024
- Ministry of Health. Immunisation Handbook 2024. Meningococcal disease. Available at: https://www.tewhatuora.govt.nz/for-health-professionals/clinical-guidance/immunisation-handbook/13-meningococcal-disease/. Accessed: May 2024
- GlaxoSmithKline NZ. BEXSERO Consumer Medicine Information 2023. Available at: https://medsafe.govt.nz/Consumers/CMI/b/bexsero.pdf. Accessed: May 2024
BEXSERO (Multicomponent meningococcal group B vaccine) is for immunisation against invasive disease caused by N. meningitidis group B from 2 months of age or as per official recommendations. BEXSERO is a prescription medicine. It is funded as part of the National Immunisation Schedule for infants and children under 5, people aged 13-25 years in close-living situations, and for people who are close contacts of a meningococcal case, or who are at high risk due to reduced immune function. See Pharmaceutical Schedule for full funding criteria. BEXSERO is also available for private purchase – you will need to pay the full cost of this medicine. Normal doctor’s charges apply. A 0.5 mL dose contains 50 mcg of Neisseria meningitidis Group B Neisseria Heparin Binding Antigen fusion protein, 50 mcg of Neisseria meningitidis Group B Neisseria Adhesin A protein, 50 mcg of Neisseria meningitidis Group B Factor H Binding Protein fusion protein, 25 mcg of Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4. BEXSERO has risks and benefits. Ask your doctor if BEXSERO is right for you. Use strictly as directed. BEXSERO should not be administered if you or your child are hypersensitive to any component of this vaccine. Very common side effects: Infants, toddlers & children: eating disorders, sleepiness, unusual crying, headache, diarrhoea, vomiting, rash, fever (≥38°C), injection site reactions, irritability, arthralgia. Use paracetamol to prevent and reduce the risk of fever in children under the age of 2. Adolescents & Adults: headache, nausea, injection site reactions, malaise, myalgia, arthralgia. If you or your child have side effects, see your doctor. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
Any information provided on the website should be discussed with an HCP and does not replace an HCP’s advice.
©2024 GSK Group of companies or its licensor. For information regarding GSK products or to report an adverse event, please call Medical Information on 0800 808 500. This site is intended for NZ audience only. GlaxoSmithKline NZ Limited, Auckland.
TAPS NP18971-PM-NZ-BEX-WCNT-230006 Date of Approval: 07 2024 Date of Expiry 07 2026